Difference between revisions of "Angiosarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
Warner-admin (talk | contribs) m (Text replacement - "prior to Paclitaxel (Taxol)" to "prior to paclitaxel") |
||
| Line 52: | Line 52: | ||
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | ||
====Supportive therapy==== | ====Supportive therapy==== | ||
| − | *[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to | + | *[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to paclitaxel |
| − | *[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to | + | *[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to paclitaxel |
| − | *[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to | + | *[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to paclitaxel |
*"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician" | *"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician" | ||
'''28-day cycle for 6 cycles''' | '''28-day cycle for 6 cycles''' | ||
Revision as of 21:29, 31 May 2023
3 regimens on this page
3 variants on this page
|
Note: this page contains regimens specific to angiosarcoma.
Guidelines
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
All lines of therapy
Bevacizumab monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Agulnik et al. 2012 (NU 04S1) | 2005-08 to 2011-04 | Phase 2 |
References
- NU 04S1: Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry
Paclitaxel monotherapy
Regimen
| Study | Evidence |
|---|---|
| Penel et al. 2008 (ANGIOTAX) | Phase 2 |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
Supportive therapy
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
References
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains dosing details in manuscript PubMed
Pazopanib monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Jones et al. 2022 (TAPPAS) | 2017-2019 | Phase 3 (C) | Pazopanib & Carotuximab | Did not meet primary endpoint of PFS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
References
- TAPPAS: Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. link to original article link to PMC article PubMed Clinical Trial Registry